<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04034862</url>
  </required_header>
  <id_info>
    <org_study_id>13011987</org_study_id>
    <nct_id>NCT04034862</nct_id>
  </id_info>
  <brief_title>Impact of DOlutegravir+Lamivudine Simplification on HIV-1 Reservoirs</brief_title>
  <acronym>IDOLTIB</acronym>
  <official_title>Impact of DOlutegravir+Lamivudine Simplification on TIssue and Blood Latent Replication-competent HIV-1 Reservoirs (IDOLTIB Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Liege</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Liege</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      For a few years, there has been a keen interest of clinicians and patients for &quot;lighter&quot;
      antiretroviral strategies based on two- or even single drug regimens rather than the
      canonical triple therapy, both as initial and maintenance therapy, despite the possibility
      that ongoing viral replication may occur in some patients under triple-therapy.

      We will therefore propose such simplification strategy (DTG/3TC) while maintaining
      triple-therapy (DTG/ABC/3TC) in a control group and will perform an in depth analysis of the
      replication-competent reservoir in blood and in tissues as well as measurements of residual
      viremia and immune chronic activation/inflammation.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2019</start_date>
  <completion_date type="Anticipated">March 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The impact of dual-therapy Dolutegravir (DTG) + Lamivudine (3TC) at the level of replication-competent reservoir (RCR) in blood and in tissues.</measure>
    <time_frame>1 year</time_frame>
    <description>Measurements of RCR in the blood and tissues (rectal biopsies)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The impact of dual-therapy Dolutegravir (DTG) + Lamivudine (3TC) on residual viremia.</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The impact of dual-therapy Dolutegravir (DTG) + Lamivudine (3TC) at the level of chronic immune activation/inflammation.</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The correlation between blood and tissues RCR in a high number of patients under suppressive antiretroviral therapy.</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The level of clonal expansion in the blood and tissue RCR</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The correlation between the size of the blood/tissues RCR and the level of chronic immune activation/inflammation.</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>2DR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Switch from 3 drug regimen (DTG+ABC+3TC) to 2 drug regimen (DTG+3TC)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3DR</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Continued 3 drug regimen treatment (DTG+ABC+3TC)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment simplification (dolutegravir lamivudine)</intervention_name>
    <description>Switch from 3 drug regimen (DTG/ABC/3TC) to 2 drug regimen</description>
    <arm_group_label>2DR</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV-infected adults receiving cART for at least 2 years

          -  DTG/3TC/ABC as cART regimen in the previous 6 months.

          -  CD4 counts higher than 200 cells per Î¼L and virological suppression for at least 2
             years (plasma HIV RNA &lt;20 copies per mL)

        Exclusion Criteria:

          -  hepatitis C or B co-infection

          -  unstable liver disease

          -  renal impairment (estimated glomerular filtration rate &lt;50 mL per min),

          -  gastrointestinal disorders that would affect the absorption of study treatment

          -  current use of drugs with significant interactions with dolutegravir

          -  current use of drugs with an impact on inflammation such as steroids.

          -  hospitalization for acute illness within the previous 8 weeks

          -  Pregnancy or breastfeeding.

          -  Known resistance to DTG or 3TC

          -  Active tuberculosis

          -  Anal or rectal lesions impeding rectal biopsies

          -  Decreased platelets count or coagulation disorder.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilles Darcis, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Liege University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gilles Darcis</last_name>
    <phone>+3243667235</phone>
    <phone_ext>+3243667235</phone_ext>
    <email>gdarcis@chuliege.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Michel Moutschen</last_name>
    <phone>+3243667235</phone>
    <phone_ext>+3243667235</phone_ext>
    <email>michel.moutschen@ulg.ac.be</email>
  </overall_contact_backup>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>July 17, 2019</study_first_submitted>
  <study_first_submitted_qc>July 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 26, 2019</study_first_posted>
  <last_update_submitted>July 24, 2019</last_update_submitted>
  <last_update_submitted_qc>July 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Liege</investigator_affiliation>
    <investigator_full_name>Gilles Darcis</investigator_full_name>
    <investigator_title>Head of clinic</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Dolutegravir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Study Protocol</ipd_info_type>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

